In experimental work conducted by our research group using non-obese diabetic severe combined immunodeficiency γ chain-deficient (NSG) mice implanted with human AML cells or healthy CD34+ cells, treatment comparisons between control T cells, anti-CD33 CAR-T cells, and anti-CD123 CAR-T cells revealed that while CAR-T cells effectively eliminated AML, they simultaneously destroyed normal hematopoietic cells. This evidence concerns the gene CD33 and acute myeloid leukemia.